Warby Parker (WRBY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.15
- Estimate
- $0.11
- Surprise
- +30.0%
- Revenue (period 2026-06-30)
- $235.5M
- Score at report (before → after)
- 4.5 → 4.5/10
Revenue source: xbrl.
How the report landed
Warby Parker (WRBY) beat the $0.11 estimate with diluted EPS of $0.15 — a large 30.0% upside surprise. TrendMatrix's engine moved from Sell (4.5/10) to Hold at 4.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates WRBY Sell at 5.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +30.0% surprise compares with a +3.4% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Thin upside margin: 8.8%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $24.35
- Price target
- $26.50
- Stop
- $22.65
- Upside to target
- +8.8%
- Reward-to-risk
- 0.8:1
The stock trades at 405.8× trailing but 39.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
WRBY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.01B
- P/E (fwd)
- 39.6
- P/E (ttm)
- 405.8
- 52-week range
- $14.96–$31.00
- Off 52-week high
- 21.5%
- RSI (14)
- 43
- Volume vs avg
- 1.42×
- Score today
- 5.1/10